Small Non-coding RNAs
Watson, Callum N; Belli, Antonio; Di Pietro, Valentina

DOI:
10.3389/fgene.2019.00364

License:
Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
https://doi.org/10.3389/fgene.2019.00364

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
Small Non-coding RNAs: New Class of Biomarkers and Potential Therapeutic Targets in Neurodegenerative Disease

Callum N. Watson1,2*, Antonio Belli1,2 and Valentina Di Pietro1,2,3

1 Neuroscience and Ophthalmology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 2 National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, 3 Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana–Champaign, Urbana, IL, United States

Neurodegenerative diseases (NDs) are becoming increasingly prevalent in the world, with an aging population. In the last few decades, due to the devastating nature of these diseases, the research of biomarkers has become crucial to enable adequate treatments and to monitor the progress of disease. Currently, gene mutations, CSF and blood protein markers together with the neuroimaging techniques are the most used diagnostic approaches. However, despite the efforts in the research, conflicting data still exist, highlighting the need to explore new classes of biomarkers, particularly at early stages. Small non-coding RNAs (MicroRNA, Small nuclear RNA, Small nucleolar RNA, tRNA derived small RNA and Piwi-interacting RNA) can be considered a “relatively” new class of molecule that have already proved to be differentially regulated in many NDs, hence they represent a new potential class of biomarkers to be explored. In addition, understanding their involvement in disease development could depict the underlying pathogenesis of particular NDs, so novel treatment methods that act earlier in disease progression can be developed. This review aims to describe the involvement of small non-coding RNAs as biomarkers of NDs and their potential role in future clinical applications.

Keywords: small non-coding RNAs, microRNAs, neurodegenerative disease, biomarkers, new therapeutic targets

INTRODUCTION

Neurodegenerative diseases (NDs) are classified as a class of disorders affecting the central nervous system and they are characterized by the progressive loss of neuronal tissues. NDs are age-dependent disorders which are increasing internationally, due to the ever increasing elderly population, which is leaving greater numbers of people subjected to the chronic, debilitating nature of these incurable diseases (Heemels, 2016). Currently, the most represented NDs are: Alzheimer’s disease (AD) with 5 million people affected in America only, followed by Parkinson’s diseases (PD) with 1 million people; multiple sclerosis (MS) 400,000; Amyotrophic lateral sclerosis (ALS) 30,000 and Huntington’s disease (HD) with 3,000 incidents (Agrawal and Biswas, 2015).

Some treatments for ND have aimed to reduce the syndrome of NDs; these include L-dopa and deep brain stimulation in PD (Groiss et al., 2009; Nagatsu and Sawadab, 2009). However, very...
few have aimed to slow or reverse ND development, and those that have been investigated e.g., stem cell therapy (Chung et al., 2002; Rachakonda et al., 2004) highlight the requirement for more research. Late diagnosis leads to strategic treatment being ineffective due to irreversible disease progression (Sheinerman and Umansky, 2013). This has been reported for example, on anti-AD therapies in late-stage clinical trials (including dimebon of Medivation and Pfizer, solanezumab of Eli Lilly and bapineuzumab of Pfizer and Johnson & Johnson). Biomarkers for early diagnosis could prevent or limit disease development through prophylactic or early treatment, which has ignited interest. Currently, the most accurate diagnosis relies on neuropathology, mainly based on autopsy, or in the measurement of cerebrospinal fluid (CSF) proteins, such as tau or Aβ, in AD, which requires invasive procedures. However, blood proteins, such as Aβ1-42 peptide in AD or cytokines for ALS or HD (Agrawal and Biswas, 2015), as well as genetics diagnostics markers such as ApoE isoforms in AD or α-synuclein or Parkin for PD, have also demonstrated potential clinical utility (Agrawal and Biswas, 2015).

Neuroimaging techniques can also help to make the correct diagnosis and monitor the progress of NDs. Magnetic resonance imaging (MRI) is one of the most widely used neuroimaging techniques used for AD (Jack et al., 2011; McKhann et al., 2011) and for dementia with Lewy bodies (DLB) (Ciurleo et al., 2014). Magnetic resonance spectroscopy (MRS) has also showed promise in early diagnosis of PD and traumatic brain injury, measuring metabolic dysfunctions and irreversible neuronal damage (Vagnozzi et al., 2008).

Recently, a new class of circulating RNAs – non-coding RNAs – have been re-evaluated and are being considered as potential biomarkers. After years of the belief that 98% of the genome was “junk” due to its non-coding nature it was realized these genes had biologically functionality. Non-coding genes include introns, pseudogenes, repeat sequences and cis/trans-regulatory elements that function as RNA without translation. Estimations have suggested that 99% of total RNA content is made up of non-coding RNA, with numbers of validated non-coding RNAs (ncRNAs) increasing every year (Palazzo and Lee, 2015).

Currently ncRNAs can be defined by length – small 18–200 nts and long >200 nts – or functionality with housekeeping ncRNAs such as ribosomal RNA (rRNAs) and transfer RNA (tRNAs) or regulatory ncRNAs like miRNA (miRNAs), small nuclear RNA (snRNAs), piwi-interacting RNA (piRNAs), tRNA derived small RNA (tsRNAs) and long non-coding RNA (lncRNAs) (Dozsmorov et al., 2013). Nonetheless, difficulty distinguishing categories persists due to the crossover of properties.

Small non-coding RNAs (sncRNAs) have diverse roles, which in conjunction with other molecules involve gene regulation through either RNA interference, RNA modification or splicingosmal involvement (Table 1). Consequently, during disease progression their expression can alter. MiRNAs are the most studied sncRNA as biomarkers with involvement in various diseases including cancers, aging and neurodegenerative disease (Calin and Croce, 2006; Grasso et al., 2014; Di Pietro et al., 2017). Other sncRNAs have shown promise as biomarkers, with links to neurodegenerative disease (Munoz-Culla et al., 2016). There is the potential for multiple sncRNA biomarkers for neurodegenerative diseases, which if found, could aid diagnosis in a clinical setting while demonstrating the processes underpinning the disease development. In future, this could produce novel therapies to treat neurodegenerative diseases using original methodologies.

In this review, we consider the evolving role of sncRNAs and discuss their involvement in neurodegenerative disease with particular emphasis on their potential as biomarkers.

### MiRNA

MiRNAs are the most studied sncRNA. Their biogenesis commences with the formation of a pri-miRNA made up of two stem-loop structure. A Drosha and DGC8R complex cleaves the pre-miRNA to form a single stem-loop pre-miRNA. Dicer cleaves the pre-miRNA to create a double stranded miRNA, which is loaded onto Argonaute family of proteins to form the miRISC complex (Figure 1A1). Accompanied to the miRISC complex, miRNAs regulate gene expression post-transcriptionally through degradation and repression of mRNA sequences by an Argonaute family protein mediated method (Figure 1A1i; O’Brien et al., 2018). A single miRNA can have multiple targets, likewise a target mRNA can be bound to by many different miRNAs, to enable more diverse signaling patterns.

MiRNAs show specific signaling in the brain, and were also found differentially expressed in bio-fluids. Although there is no consistent consensus on particular miRNAs or brain area yet, and no specific miRNA overlap between brain tissues and bio-fluids (as reported in Table 2) these findings certainly provide insights in the study of NDs pathogenesis.

MiRNAs are best studied in Alzheimer’s disease (AD), which manifests itself as deposition of neurofibrillary tangles (NFT) and extracellular amyloid-β (Aβ), before neuronal degeneration and clinical symptoms materialize in the form of behavioral changes such as memory issues. NFT, Aβ and neuronal degeneration have been associated with dysregulation of miRNA gene expression, which could emanate from altered Aβ or Tau metabolism. MiRNAs effect Aβ metabolism by interacting with amyloid precursor protein (APP) through direct binding of the 3’untranslated region (3’UTR) to the APP mRNA, indirect inhibition through downregulation of Beta-secretase 1 (BACE1) and ATP-binding cassette transporter (ABCA1) or regulating alternative APP splicing. MiRNAs also affect Tau through regulation of microtubule associated protein tau (MAPT)
FIGURE 1 | Biogenesis of sncRNAs and an example of their biological function. A (i) MicroRNAs are single stranded ~22 bp sequences formed from double stranded precursors (ii) that prevent mRNA translation. B (i) Small nuclear RNAs biogenesis is made up of two classes Sm class snRNA and Lsm-class snRNA (Not shown), (ii) which form the major and minor spliceosome. C (i) Small nuclear RNAs have two different classes formed using different machinery; Box C/D RNA and Box H/ACA RNA, (ii) which cause methylation and pseudouridylation respectively. D (i) Piwi interacting RNAs are formed by either primary alone or by both primary and secondary biogenesis (ii) that prevent transposon translation through methylation. E (i) Transfer RNA cleavage forms transfer RNA derived fragments to be formed, (ii) which can prevent translation or cause gene repression.

splicing, affecting tau isoforms 3R and 4R. Direct or indirect binding either modulates phosphorylated Tau-associated protein kinases or influences degradation of phosphorylated tau by binding 3’-UTR BCL2 associated athanogene 2 (BAG2) mRNA (Zhao et al., 2017).

MiRNAs have an established involvement in neurobiological functions and pathogenesis of numerous other neurodegenerative diseases (Serafin et al., 2014; Fransquet and Ryan, 2018; Ricci et al., 2018). Mitochondrial dysfunction caused by miRNA dysregulation leads to oxidative stress, which causes cell death, α-synuclein aggregation and neurodegeneration known to be present in PD (Spano et al., 2015). In ALS, both TAR DNA binding protein (TARDBP) and fused in sarcoma (FUS) are well-established causative genes, which are involved in miRNA processing. TARDBP has specific roles in facilitation of post-transcriptional processing achieved through association directly with miRNA or processing factors such as Dicer (Kawahara and Mieda-Sato, 2012). FUS regulates miRNA-mediated gene silencing through facilitation of the interaction between miRNA, mRNA and RISC components (Zhang et al., 2018). In HD, a miRNA formulation is being trailed as therapeutic agents to alter the aberrant Huntingtin (HTT) protein expression (Aronin and DiFiglia, 2014).

MiRNA involvement in ND development has demonstrated the capability of distinguishing between disease subtypes and shown promise for future stratification. For example in AD, 30 differentially regulated miRNAs found in the brain and blood of AD patients were assigned to different Braak stages, a methodology for classifying AD pathology, with 10 associated with Braak stage III (hsa-mir-107, hsa-mir-26b, hsa-mir-30e, hsa-mir-34a, hsa-mir-485, hsa-mir200c, hsa-mir-210, hsa-mir-146a, hsa-mir-34c, and hsa-mir-125b) (Swarbrick et al., 2019). Likewise in PD, miR-331-5p is differentially expressed in plasma of early onset Parkinson’s disease (EOPD) patients, which was not seen in late onset Parkinson’s disease (LOPD) patients (Cardo et al., 2013; Table 2). Studies comparing between subtypes of NDs are still in the minority and more are required to understand the true capability of miRNA markers in stratification of NDs.

SMALL NUCLEAR RNAs

Small nuclear RNAs (snRNAs), the component parts of the spliceosome – responsible for removal of non-coding introns from precursor mRNA – are highly conserved uridine rich sequences with five snRNAs making up its spine; U1, U2, U4, U5,
<table>
<thead>
<tr>
<th>Neurodegenerative disease</th>
<th>Source</th>
<th>miRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s disease</td>
<td>Whole blood</td>
<td>miR-106b-5p, miR-106a-5p, miR-107, miR-9-5p (Yilmaz et al., 2016a) Let-7d-5p, Let-7f-5p, miR-107, miR-26a-5p, miR-26b-5p (Leidinger et al., 2013) miR-142-5p (Sorensen et al., 2016)</td>
</tr>
<tr>
<td>Brain tissues</td>
<td>miR-9, miR-128 (Lukiw, 2007) miR-26a, miR-27b, miR-30e-5p, miR-34a, miR-92, miR-125, miR-145, miR-200c, miR-381, miR-422a, miR-423</td>
<td>miR-9, miR-132, miR-148b, miR-212 (Cogswell et al., 2008) miR-197, miR-511, miR-320, let-7i, miR-101, miR-106b, miR-150, miR-181c, miR-19b, miR-22, miR-210, miR-26b, miR-29b-1, miR-363, miR-9, miR-93 (Hebert et al., 2006)</td>
</tr>
<tr>
<td></td>
<td>CSF</td>
<td>miR-29a (Shioya et al., 2010) miR-26b (Absalon et al., 2013) miR-370, miR-328, miR-138, miR-132 and miR-15a (Bekris et al., 2013)</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>let-7f, miR-105, miR-125a, miR-135a, miR-138, miR-141, miR-151, miR-186, miR-191, miR-197, miR-204, miR-205, miR-216, miR-302b, miR-30a5p, miR-30a2p, miR-30b, miR-30c, miR-30d, miR-32, miR-345, miR-362, miR-371, miR-374, miR-375, miR-380-3p, miR-429, miR-448, miR-449, miR-501, miR-517, miR-517b, miR-518b, miR-518f, miR-520a*, miR-526a, miR-10a, miR-10b, miR-125, miR-126*, miR-127, miR-142-5p, miR-143, miR-146b, miR-154, miR-15b, miR-181a, miR-181c, miR-194, miR-195, miR-199a*, miR-214, miR-221, miR-328b, miR-422, miR-451, miR-455, miR-497, miR-99a (Bekris et al., 2013)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-142-3p, miR-483-5p (Nagaraj et al., 2017) miR-125b-5p, miR-29b-3p, miR-3065-5p, miR-342-3p/5p (Lugli et al., 2015) miR-107 (Wang et al., 2008) miR-34a (Bhatnagar et al., 2014) miR-146a, miR-34a (Kikko et al., 2014) Let-7d-5p, Let-7g-5p, miR-142-3p, miR-15b-5p, miR-191-5p (Kumar et al., 2013)</td>
</tr>
<tr>
<td>Early onset Parkinson’s disease (EOPD)</td>
<td>Whole blood</td>
<td>miR-1, miR-22, miR-29a (Margs et al., 2011)</td>
</tr>
<tr>
<td>Brain tissues</td>
<td>miR-34b, c (Minones-Moyano et al., 2011) miR-331-5p (Cardo et al., 2013)</td>
<td></td>
</tr>
<tr>
<td>Plasma</td>
<td>miR-141, miR-146b-5p, miR-193a-3p, miR-214 (Dong et al., 2016)</td>
<td></td>
</tr>
<tr>
<td>Serum</td>
<td>miR-103a, miR29a, miR-30b (Serafin et al., 2015) miR-3143, miR-335-3p, miR-4671-3p, miR-561-3p, miR-579-3p (Yilmaz et al., 2016b)</td>
<td></td>
</tr>
<tr>
<td>Late onset Parkinson’s disease (LOPD)</td>
<td>Whole Blood</td>
<td>miR-34b, c (Minones-Moyano et al., 2011) miR-181a, b, c, d, miR-22, miR-29a, b, c (Liao et al., 2013) miR-106a, miR-21, miR-224, miR-26b, miR-301b, miR-373 (Alvarez-Erviti et al., 2013) miR-206 (Cho et al., 2013) miR-135b, miR-188, miR-455-5p, miR-548d (Cardo et al., 2014) Let-7i-3p, miR-10b-3p, miR-1224, miR-127-3p, miR-127-5p, miR-16-5p, miR-184, miR-29a-3p (Hoss et al., 2016) miR-144, miR-145, miR-199b, miR-221, miR-488, miR-543, miR-544, miR-7 (Tatura et al., 2016)</td>
</tr>
<tr>
<td>Brain tissues</td>
<td>Let-7i, miR-34a (Schipper et al., 2007)</td>
<td>miR-29b (Villa et al., 2013) Let-7i, miR-34a (Schipper et al., 2007)</td>
</tr>
</tbody>
</table>
### TABLE 2 | Continued

<table>
<thead>
<tr>
<th>Neurodegenerative disease</th>
<th>Source</th>
<th>miRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amyotrophic lateral sclerosis (ALS)</strong></td>
<td>CSF</td>
<td>Let-7a-5p, miR-1242-5p, miR-127-3p, miR-128, miR-132-3p, miR-19a,b, miR-212-3p, miR-370, miR-409-3p, miR-4448, miR-485-5p, miR-873-3p (Burgos et al., 2014)</td>
</tr>
<tr>
<td></td>
<td>CSF</td>
<td>Let-7g-3p, miR-103a, miR-10a-5p, miR-119a, miR-126, miR-127-3p, miR-132-5p, miR-136-3p, miR-151, miR-153, miR-16-2, miR-19b-3p, miR-22, miR-26a, miR-28, miR-29a,c, miR-301a, miR-30b, miR-331-5p, miR-370, miR-409-3p, miR-433, miR-485-5p, miR-873-3p (Gu et al., 2015)</td>
</tr>
<tr>
<td></td>
<td>CSF</td>
<td>miR-1249, miR-1274b, miR-150, miR-18b, miR-199b, miR-20a, miR-21, miR-320a,b, miR-378c, miR-4293, miR-671, miR-769, miR-92b (Soreq et al., 2013)</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>miR-222, miR-505, miR-626 (Khoo et al., 2012)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-19b, miR-29a,c (Botta-Orfila et al., 2014)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-133b (Zhao et al., 2014)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-29a,b,c (Sai et al., 2017)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-146a, miR-214, miR-221, miR-29c (Ma et al., 2016)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-1294, miR-16-2-3p, miR-30a,e, miR-338-3p (Burgos et al., 2014)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-148b, miR-223, miR-24, miR-30c, miR-324-3p (Vallelunga et al., 2014)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-15b, miR-181a, miR-185, miR-195, miR-221 (Ding et al., 2016)</td>
</tr>
<tr>
<td></td>
<td>PSIMCs</td>
<td>miR-126, miR-126*, miR-147, miR-151-3p,5p, miR-199a-3p,5p, miR-199b, miR-19b, miR-26a, miR-28-5p, miR-29b,c, miR-301a, miR-30b,c, miR-335, miR-374a,b (Martins et al., 2011)</td>
</tr>
<tr>
<td></td>
<td>Whole Blood</td>
<td>miR-155, miRNA-146a (Caggii et al., 2018)</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>miR-4649-5p, miR-4299 (Takahashi et al., 2015)</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>miR-424, miR-206 (de Andrade et al., 2016)</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>miR-206, Pairs miR-206/miR-338-3p, miR-9*/miR-129-3p, miR-335-5p/miR-338-3p (Sheinerman et al., 2017)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-132-3p, miR-132-5p, miR-143-3p, miR-143-5p, let-7b (Freischmidt et al., 2013)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-206, miR-106b (Toivonen et al., 2014)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-4745-5p, miR-3666, miR-4530, miR-1915-3p (Freischmidt et al., 2014)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-1825, miR-1234-3p (Freischmidt et al., 2015)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-123a, miR-132b, miR-146a, miR-149*, miR-27a (Tasca et al., 2016)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-1, miR-133a-3p, miR-133b, miR-144-5p, miR-192-3p, miR-195-5p, miR-19a-3p, let-7d-3p, miR-320a, miR-320b, miR-320c, miR-425-5p, miR-139-5p (Flaheja et al., 2018)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-206, miR-143-3p, miR-374b-5p (Waler et al., 2017a)</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>miR-142-3p, miR-1249-3p (Matamala et al., 2018a)</td>
</tr>
<tr>
<td></td>
<td>Brain tissues</td>
<td>miR-9/miR-9*, miR-124a, miR-132 (Packer et al., 2008)</td>
</tr>
<tr>
<td></td>
<td>Brain tissues</td>
<td>miR-10b-5p, miR-196a-5p, miR-615-3p, miR-10b-3p, miR-1298-3p, miR-196b-5p, miR-302a, miR-1247-5p, miR-144-5p, miR-223-3p, miR-3200-5p, miR-320a-5p, miR-1284, miR-6734-5p, miR-144-5p, miR-138-2-5p, miR-431-5p, miR-132-3p, miR-200c-3p, miR-23b-3p, miR-448, miR-486-3p, miR-490-5p, miR-5695, miR-885-3p, miR-1224-5p, miR-1298-5p, miR-142-3p, miR-346, miR-891a-5p, miR-16-2-3p, miR-383-3p, miR-148a-3p, miR-199a-5p, miR-4449, miR-106a-5p, miR-142-5p, miR-549a, miR-214-5p, miR-5880, miR-3065-5p, miR-224-5p, miR-4787-5p, miR-452-5p, miR-129-1-3p, miR-4443, miR-101-5p, miR-483-5p, miR-2114-5p, miR-1185-1-3p, miR-670-3p, miR-129-5p, miR-135b-5p, miR-194-5p, miR-208b-3p, miR-448, miR-886-5p, miR-126-5p, miR-34c-5p, miR-219-1-3p, miR-150-5p, miR-486-5p, miR-433-3p, miR-219b-3p, miR-548b, miR-663b, miR-148a-5p, miR-29a-3p, miR-320b, miR-181a-3p, miR-153-5p, miR-28-5p, miR-7-2-3p, miR-877-5p, miR-3687, miR-4516, miR-3139, miR-663a, miR-34b-3p, miR-1538 (Hoss et al., 2015a)</td>
</tr>
<tr>
<td></td>
<td>CSF</td>
<td>miR-520f-3p, miR-158b-3p, miR-4317, miR-3928-5p, miR-8082, miR-140-5p (Reed et al., 2018)</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>miR-100-5p, miR-486-5p (Hoss et al., 2015b)</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>miR-34b (Saughvin et al., 2011)</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>miR-877-5p, miR-223-5p, miR-30d-5p, miR-128, miR-22-5p, miR-222-3p, miR-338-3p, miR-130b-3p, miR-425-5p, miR-628-3p, miR-361-5p, miR-942 (Diez-Planelles et al., 2016)</td>
</tr>
</tbody>
</table>

*Passenger miRNA strand.
TABLE 3 | Interactions of small non-coding RNAs with Neurodegenerative diseases.

<table>
<thead>
<tr>
<th>snoRNA major spliceosome</th>
<th>Disease</th>
<th>Interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD</td>
<td>U1 snRNPs present in cytoplasmic aggregates</td>
<td></td>
</tr>
<tr>
<td>SMA</td>
<td>SMN1 gene dysregulation alters U snRNA levels</td>
<td></td>
</tr>
<tr>
<td>Neurodegeneration</td>
<td>U2 snRNA mutation alters pre-mRNA splicing</td>
<td></td>
</tr>
<tr>
<td>ALS</td>
<td>A disease related di-peptide repeat</td>
<td></td>
</tr>
<tr>
<td>FTD</td>
<td>C90RF72 interacts with U2 snRNP</td>
<td></td>
</tr>
<tr>
<td>RP</td>
<td>Mutation found in PRPF4 which encodes U4/U6 di-snoRNA protein</td>
<td></td>
</tr>
<tr>
<td>snRNA minor spliceosome</td>
<td>ALS</td>
<td>Decreased U12 snoRNA in spinal motor neurones</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Decreased TDP-43 disrupts U12 mediated pre-mRNA splicing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FUS mutants cannot bind U11 so decreased minor intron splicing</td>
</tr>
<tr>
<td>snoRNA</td>
<td>AD</td>
<td>Differential expression of two C/D box snoRNAs e307 and e470 in mouse model</td>
</tr>
<tr>
<td></td>
<td>ASD</td>
<td>SNORD115 duplication in mouse causes abnormal brain development</td>
</tr>
<tr>
<td>pRNA</td>
<td>AD</td>
<td>9 piRNAs found to be differentially regulated in AD risk variant patients (6 APOE and 3 RNU6-560P)</td>
</tr>
<tr>
<td>PD</td>
<td>70 differentially expressed piRNAs in combined patient tissue and cells</td>
<td></td>
</tr>
<tr>
<td>tRNA</td>
<td>ALS</td>
<td>ANG mutants implicated in pathogenesis</td>
</tr>
<tr>
<td></td>
<td>PD</td>
<td>A subset of ALS-associated ANG mutants</td>
</tr>
<tr>
<td></td>
<td>Intellectual disability</td>
<td>N52un2 mutation causes 5'tRNA accumulation</td>
</tr>
<tr>
<td></td>
<td>PCH</td>
<td>CLP1 gene mutation disruption of tRNA splicing</td>
</tr>
<tr>
<td></td>
<td>Neurodegenerative patient</td>
<td>KAE1 gene mutation alters tRNA modification</td>
</tr>
</tbody>
</table>

and U6. These snoRNAs combine with partner proteins to form the small nuclear ribonucleoprotein (snRNPs) complex, which is essential pre-mRNA splicing to enable production of functional mRNA for protein translation.

Sm-class snoRNAs are synthesized by RNA polymerase II and after transcription contain a 7-methylguanosine cap, Sm-protein binding site and 3′ and after transcription contain a 7-methylguanosine cap, Sm-protein binding site and 3′ polyadenylation (PCPA) at the 3′ poly-A site. This affects splicing and could demonstrate a novel AD causing pathology (Cheng et al., 2017) (Table 3).

U snRNAs are also associated with spinal muscular atrophy (SMA). SMN1 gene dysregulation alters U snRNA levels through its role in U snRNA biosynthesis; nonetheless, the underlying pathology is still unclear (Zhang et al., 2013). Many studies have proposed a reduction in U snRNAs is key to SMA pathology due to their involvement in mRNA processing, with U1 and U11 of particular interest (Gabanna et al., 2007; Zhang et al., 2008). In contrast, U snRNAs can accumulate in the motor neurons of ALS patient spinal cords when compared to control patients, to cause defects showing that U snRNA level can depict disease state, depending of cell type (Tsuiji et al., 2013).

More recently, when considering induced pluripotent stem cell (iPSC) derived motor neurones cultures, a study suggested that an imbalanced ratio of variant U1 to U1 might cause the SMA phenotype rather than an overall reduction in U1 snRNA (Vazquez-Arango et al., 2016). Demonstrating that purely measuring U snRNA level may be an oversimplified measurement and variant U snRNA could indicate the underlying pathophysiology of aberrant spliceosome related neurodegeneration.

Other U snRNAs studied in neurodegenerative disease include U2. A U2 snRNA mutation causes neuron degeneration, through altering pre-mRNA splicing at select splice sites that are associated with alternative pre-mRNA splicing (Jia et al., 2012). In addition, a dipeptide repeat (C90RF72) linked to both ALS and frontotemporal dementia (FTD), interacts and interferes with U2 snRNP. In patient derived cells, this led to mislocalisation but mis-splicing linked to ALS/FTD has yet to be established (Yin et al., 2017).

Mutations found within the gene PRPF4 – which encodes hPrp4 a U4/U6 di-snoRNA protein – undertake an important role in the development of retinitis pigmentosa (RP) (Chen et al., 2014). hPrp4 is known to interact with
CypH and hPrp3 to regulate the stability of the tri-snRNP, U4/U6.U5. Thus, aberrant splicing could cause RP through direct or indirect mechanisms that have been hypothesized, but not defined.

The minor spliceosome has ND relevance as in ALS, TDP-43 functionality decreases (Columbrita et al., 2012), which reduces the number Gemini of coiled bodies (GEMs). GEMs contribute to U12 snRNA biogenesis, so in spinal motor neurones of ALS patients there was a decrease of U12 snRNA and U11/U12 snRNP, which may disrupts pre-mRNA splicing (Ishihara et al., 2013). Additionally, an ALS mutant (P525L) cannot promote minor intron splicing due to an aberrant FUS gene that routinely binds to U11 snRNP to direct splicing. This leads to mislocalisation of FUS-trapped U11 and U12 snRNAs, which form aggregates in the cytoplasm so incorrect splicing results (Reber et al., 2016). In addition, a cerebral ataxia mutation RNU12 causes minor intron retention in homozygous mutant patients (Elsaid et al., 2017). When combined this demonstrates a likely role for minor intron splicing in motor neuron maintenance.

**SMALL NUCLEOLAR RNAs**

Small nucleolar RNAs (SnoRNAs) modify RNA through there conserved motifs, with boxes C/D guiding methylation and H/ACA guiding pseudouridyllation, respectively (Ohtani, 2017; Figure 1Ci). Each class of snoRNAs displays a unique secondary structure composed of conserved proteins to form the defined C/D and H/ACA snoRNPs. SnoRNAs mainly target rRNA to modify functionally important regions of the ribosome (Decatur and Fournier, 2002) but other purposes include pre-rRNA endonucleolytic processing (Tollervey and Hurt, 1990), guiding snRNAs such as U6 snRNA (Tycowski et al., 1998) and more recently mRNA guiding (Sharma et al., 2016) or regulation of alternative splicing in pre-mRNAs (Falaleeva et al., 2016).

Box C/D snoRNP biogenesis commences when a protein complex of SNU13 and NOP58 is pre-formed and loaded onto the snoRNA with the help of HSP90/R2TP. This recruits assembly factors and the pre-snoRNPs are transferred to the Cajal bodies where final processing occurs. Box H/ACA RNPs biogenesis starts by SHQ1 and DKC1 combining to prevent to non-specific RNAs binding. SHQ1 is released with the help of the R2TP complex allowing DKC1 to bind H/ACA RNAs at the site of transcription. Numerous assembly factors including NHP2, NOP10, and NAF1 are present during this pre-snoRNP form. When NAF1 – which binds the C-terminal domain of RNA polymerase II to keep H/ACA RNP inactive – is replaced by GAR1, mature and functional H/ACA RNPs are produced. Both polymerase II to keep H/ACA RNP inactive – is replaced by GAR1, mature and functional H/ACA RNPs are produced. Both

Despite the fact that autism spectrum disorder (ASD) might not be considered a neurodegenerative disease. Studies have found links in ASD with numerous snoRNA genes found to be differentially expressed using RNA-seq (Wright et al., 2017). Duplication of SNORD115 in mouse chromosome 7 that mirrors human chromosome 15q11-13 – duplication of this is one of the most common chromosomal abnormalities in ASD – has been shown to increase SNORD115 levels and results in abnormal brain development. In addition, SNORD115 (HBII-48 and HBII-52) levels are dysregulated in superior temporal gyrus of human ASD brain samples, which could explain 5-HT changes (Gabriele et al., 2014) and alternative splicing seen in ASD (Voineagu et al., 2011) as HBII-52 may regulate 5-HT2C receptor mRNA levels (Stamova et al., 2015) as well as alternative splicing (Kishore et al., 2010).

Another study demonstrated that maternal alcohol consumption in pregnancy alters the C/D box RNA levels in brain cells during abnormal fetal development. DNA methylation, microRNA and snoRNA levels altered with emphasis on SNORD115 increasing and SNORD116 decreasing (Laufer et al., 2013).

**PIWI-INTERACTING RNA**

Piwi-Interacting RNAs (PiRNAs) are a diverse range of small RNAs that are highly enriched in the germline tissues. They interact with PIWI-class Argonaute proteins with sequence bias for only the first 5’ nucleotide to be a Uracil. This diverse population can be mapped back to distinct areas of the genome known as piRNA clusters, which contain highly enriched areas of fragmented dysfunctional transposable element (TE) sequences. These are thought to emanate from the memory of previous TE invasions, and can be utilized to protect against TEs (Toth et al., 2016). In addition, PIWI proteins function at the chromatin level by guiding DNA methylation and deposition of repressive histone marks to silence TE transcription (Le Thomas et al., 2013; Figure 1Dii).

The biogenesis of piRNAs gives rise to two different forms primary and secondary of 26–30 bps in length, stemming from single-stranded precursors (Yan et al., 2011; Mani and Juliano, 2013), which are best studied in Drosophila. Primary piRNAs biogenesis is poorly defined but precursors of around 200 bp stemming nearly entirely from piRNA clusters are cleaved – Zucchini (ZUC) is thought to do this – to enable loading onto a PIWI protein in association with other factors (Figure 1D). This piRNA-PIWI complex interacts with TEs to prevent insertion through methylation or transcriptional repression, thereby affecting gene expression (Toth et al., 2016).

In Drosophila, secondary piRNAs are formed through a more defined “ping-pong” pathway, which utilizes the primary piRNAs formed from TE fragments present in piRNA clusters loaded onto Aubergine (AUB) to find complementary antisense TE transcripts (Figure 1D). Once found the complementary TE mRNA binds, and is cleaved ten nucleotides along from the 5’ end by AUB, which terminates its function. Additionally it creates a new 5’ end and piRNA precursor, which accompanied by
AGO3 is processed into secondary piRNA. The secondary piRNA promotes the development of more cluster-derived piRNAs – it is representative of the sense TE strand – through complementary cluster transcripts to develop a greater repertoire against active TEs (Toth et al., 2016; Figure 1Dii).

Originally piRNAs were solely thought to be present in germline cells, more recently they have been found in other areas of the body including blood (Yang et al., 2015), blood plasma (Freedman et al., 2016) and the brain (Roy et al., 2017) as well as interacting with diseases in the liver (Rizzo et al., 2016), cardiovascular system (Loche and Ozanne, 2016) and brain (Roy et al., 2017) demonstrating their roles are far-reaching. In neurodegenerative disease there have been recent studies on PD and AD.

Risk variants APOE (rs2075650) and RNU6-560P (rs10792835 + rs3851179) have been linked with AD through genome-wide association studies (GWAS). These risk variants were significantly correlated with nine (6 APOE and 3 RNU6-560P) different piRNAs, showing regulatory capabilities (Guo X. et al., 2017). PiRNA dysregulation may be integral to the development of AD through aberrant downstream signaling. The link to pathogenesis in AD was clarified in three AD studies on PD and AD.

Numerous neurodegenerative disorders are associated with tRFs. ANG mutants show reduced ribonuclease (RNase) activity and were first implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) (Greenway et al., 2006). Latterly, a subset of the ALS-associated ANG mutants were observed in Parkinson’s disease (PD) patients (van Es et al., 2011). Recombinant ANG can improve life span and motor function in an ALS [SOD1 (G93A)] mouse model, demonstrating that tRFs may have an important role in motor neuron survival (Kieran et al., 2008) (Table 3).

The link between ANG-induced tRNAs, cellular stress and neurodevelopment disorders was strengthened with the finding of NSun2 (Blanco et al., 2014). Mutations in the cytosine-5 RNA methyltransferase NSun2 have been shown to cause intellectual disability and a Dubowitz-like syndrome in humans (Abbasi-Moheb et al., 2012; Martinez et al., 2012). NSun2 methylates two different cytosine residues of tRNA. Without NSun2, cytosine-5 RNAs are not methylated, which increases the stress-induced ANG-mediated endonucleolytic cleavage of tRNAs and ribonuclease P (RNase P) and ribonuclease Z cleave the transcribed pre-tRNA at the 5′ leader sequence and 3′ polyuracil (poly –U) tail, respectively, before tRNA nucleotidyl transferase adds a 3′CCA tail (Figure 1Ei). Many post-transcriptional modifications will occur during maturation and only tRNAs appropriately processed will leave the nucleus via nuclear receptor-mediated export process, with wrongly processed terminating. The mature tRNAs are between 73–90 nts in length and contain a clover-leaf shaped secondary structure, composing of a D-loop, an anticodon loop, a T-loop, a variable loop and an amino acid acceptor stem (Kirchner and Ignatova, 2015). The mature of pre-tRNA can be cleaved – into specific products unlike previously thought – into two main categories of cleaved tRNAs have been categorized; (1) tRNA-halves, (2) tRNA derived fragments.

tRNA halves are produced by cleavage of the anticodon loop giving rise to two halves: 30–35 nt 5′-tRNA halves and 40–50 nt 3′tRNA halves (Li and Hu, 2012; Figure 1Eii). A subtype of tRNA halves known as tRNA-derived stress-induced RNAs (t(i)RNAs) are by-products of stress. They induce cleavage by angiogenin (ANG) – a ribonuclease – of mature cytoplasmic tRNAs (Yamasaki et al., 2009).

tRNA derived fragments (tRFs) are produced from either pre-tRNAs or mature tRNAs (Figure 1Ei). Four main types have been established stemming from the fragment location on tRNAs: 5-tRFs, 3-tRFs, 1-tRFs, and 2-tRFs. 5-tRFs – located most 5′-trailer fragment of pre-tRNAs derived from either RNaseZ or ELAC2, this usually commences after the D-loop of tRNAs by Dicer, with adenine being present at the 3′ ends. Further subdivision classifies 5-tRFs isoforms into “a” (~15 nts), “b” (~22 nts) and “c” (~30 nts) (Kumar et al., 2015; Lee et al., 2009). 3-tRFs result from cleavage by Dicer, ANG or another member of the Ribonuclease A superfamily of the T-loop, containing a CCA tail sequence (18–22 nts) (Lee et al., 2009; Maraia and Lamichhane, 2011; Kumar et al., 2015). 1-tRFs are formed by the cleavage of the 3′-tailer fragment of pre-tRNAs by either RNaseZ or ELAC2, this usually commences after the 3′-ends of mature tRNA and contains a poly-U 3′-end (Lee et al., 2009; Liao et al., 2010). 2-tRFs, less known about but may be formed from the anticodon loop (Goodarzi et al., 2015).

TRANSFER RNAs

Transfer RNAs (tRNAs) are the most abundant form of sncRNA, making up 4–10% of all cellular RNAs. Previously thought to be static contributors to gene expression, acting as an adaptor molecule in translation. Recently it has been found that small non-coding tRNAs have unique function that enable wider signaling and dynamic regulation of various functions (Gebetsberger and Polacek, 2013).

Mature tRNA is formed through transcription of precursor tRNA (pre-tRNA) using RNA polymerase III. Endonucleolytic
so 5'-tRNAs accumulate. Accumulation of these factors leads to cell death in hippocampal and striatal neurons because of translational repression leading to cellular stress. Subsequently, NSun2 knockout mice show reduced neuronal size and impaired formation of synapses, which could explain the impairment of NSun2 gene mutation patients (Blanco et al., 2014).

A mutation in CLP1 gene (R140A) – a RNA kinase involved in tRNA splicing – is present in pontocerebellar hypoplasia (PCH) patients, a heterogeneous group of inherited neurodegenerative disorders characterized by the loss of motor neurons, muscle paralysis, impaired development of various parts of the brain and differential tRNA splicing (Karaca et al., 2014; Schaffer et al., 2014). The role of CLP1 in RNA splicing means the mutant gene has reduced kinase activity and affinity to the tRNA endonuclease complex (TSEN), impairing pre-tRNA cleavage and elevating unspliced pre-tRNAs in patient derived neurons (Schaffer et al., 2014). TSEN cuts the transcript at 3' intron-exon junctions, so the absence of CLP1 means 5'-unphosphorylated tRF cannot interact with the pre-tRNA3' 3'-exon and subsequent splicing steps are interrupted (Cassandrini et al., 2010).

N°-threonyl-carbamoyl-adenosine (t^A) is a complex modification of adenosine involved in cytoplasmic tRNA modification. It is located next to the anticodon loop of many tRNAs that decode ANN codons, at position 37 (t^A37). Recently, a biosynthetic defect in the t^A molecule was found in two phenotypically neurodegenerative patients, implicating tRNA modification in neuronal maintenance (Edvardson et al., 2017).

Although, tRNA-derived small non-coding RNAs, have already demonstrated a role in cancer progression (Sun et al., 2018), their role as biomarkers in NDs has not been fully investigated yet.

However, animal studies showed 13 dysregulated tRFs in brain samples of SAMP8 mouse model for AD. In particular, four were upregulated (AS-tDR-011775, AS-tDR-011438, AS-tDR-006835 and AS-tDR-005058) and 9 down regulated (AS-tDR-013428, AS-tDR-011389, AS-tDR-009392, AS-tDR012690, AS-tDR-010654, AS-tDR-008616, AS-tDR-010789, AS-tDR-011670, and AS-tDR-007919), demonstrating their potential involvement of tRFs in early detection of AD.

**CONCLUSION**

The key problem with the ND field is the lack of understanding in the events preceding the development of protein-based markers – such as Tau – currently used to diagnose NDs. By this stage, the diseases become more difficult to treat.

SncRNAs play an important regulatory role in the maintenance of the homeostatic brain. Therefore, changes in their concentration levels can be indicative of mechanistic changes that could precede protein-based markers. One single sncRNA biomarker is unlikely to differentiate between diseases. However, a combination of sncRNA biomarkers could be illustrative of the mechanistic development of NDs to enable early diagnosis, enhanced disease monitoring as well as defining subtle differences between NDs. Consequently, novel treatment methods directly related to their mechanistic underpinning of specific NDs, and potentially other brain related pathologies can be envisaged.

Novel, less-well studied sncRNAs could be integral to understanding the overall disease progression. So new methodologies may be necessary to quantify these changes and allow for future biomarker development.

**AUTHOR CONTRIBUTIONS**

CW drafted the manuscript. AB and VDP critically revised the manuscript.

**FUNDING**

This study was funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

**REFERENCES**


miRNA expression during the development of Alzheimer’s disease is a critical area of research. Several studies have explored the role of miRNAs in various neurodegenerative diseases, including Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS).

Shioya et al. (2010) identified specific miRNAs that were altered in Alzheimer’s disease brains. These findings suggest that miRNAs play a role in the pathogenesis of Alzheimer’s disease by targeting key neuronal functions.

Sheinerman et al. (2013) demonstrated that early detection of neurodegenerative diseases using circulating brain-enriched miRNAs is feasible. This approach could potentially be used for early diagnosis and monitoring of the disease progression.

Sharma et al. (2016) investigated the global miRNA expression and identified potential biomarkers for detecting and differentiating neurodegenerative diseases. Their findings highlight the potential of miRNA-based approaches for disease diagnosis.

Watson et al. (2019) systematically reviewed the potential biomarkers for detecting and differentiating neurodegenerative diseases. Their work underscores the importance of miRNAs as biomarkers in these diseases.

ALs and SMA. EMBO Mol. Med. 5, 221–234. doi: 10.1002/emmm.20120 2303


Hypothesis: do miRNAs targeting the leucine-rich repeat kinase 2 gene (LRRK2) influence Parkinson’s disease susceptibility? *OMICS* 20, 224–228. doi: 10.1089/omi.2016.0040

Evidence that C9ORF72 dipeptide repeat proteins associate with U2 snRNP to cause Mis-splicing in ALS/FTD Patients. *Cell Rep.* 19, 2244–2256. doi: 10.1016/j.celrep.2017.05.056


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Watson, Belli and Di Pietro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.